1-4 of 4
Alexandra Vandegrift
Close
Sort by
Journal Articles

Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience

Clinical Trials & Observations
Anthony R. Mato, Chadi Nabhan, Paul M. Barr, Chaitra S. Ujjani, Brian T. Hill, Nicole Lamanna, Alan P. Skarbnik, Christina Howlett, Jeffrey J. Pu, Alison R. Sehgal, Lauren E. Strelec, Alexandra Vandegrift, Danielle M. Fitzpatrick, Clive S. Zent, Tatyana Feldman, Andre Goy, David F. Claxton, Spencer Henick Bachow, Gurbakhash Kaur, Jakub Svoboda, Sunita Dwivedy Nasta, David Porter, Daniel J. Landsburg, Stephen J. Schuster, Bruce D. Cheson, Pavel Kiselev, Andrew M. Evens
Journal: Blood
Blood (2016) 128 (18): 2199–2205.
https://doi.org/10.1182/blood-2016-05-716977
Published: 2016
Includes: Supplemental data
Journal Articles

Bruton's Tyrosine Kinase Inhibition Is Associated with Manageable Cardiac Toxicity

Alison Romisher, Joseph Carver, MD, Stephen J. Schuster, MD, Jakub Svoboda, MD, Alexandra Vandegrift, BA, Allison Rago, BSN, Rupal O'Quinn, MD, Bonnie Ky, MD, Anthony R. Mato, MD
Journal: Blood
Blood (2015) 126 (23): 4529.
https://doi.org/10.1182/blood.V126.23.4529.4529
Published: 2015
Journal Articles

Favorable Outcomes in CLL Pts with Alternate Kinase Inhibitors Following Ibrutinib or Idelalisib Discontinuation: Results from a Large Multi-Center Study

Anthony Mato, MD, Chadi Nabhan, MD, Paul M. Barr, MD, Chaitra S. Ujjani, MD, Brian T. Hill, MD PhD, Nicole Lamanna, MD, Alan P Skarbnik, MD, Christina Howlett, PharmD, BCOP, Jeffrey J Pu, MD PhD, Alison R. Sehgal, MD, Lauren E. Strelec, BA, Alexandra Vandegrift, BA, Allison Rago, BSN, Clive S Zent, MD, Tatyana Feldman, MD, Andre Goy, MD, David F. Claxton, MD, Spencer Henick Bachow, MD, Gurbakhash Kaur, MD BS, MA, Jakub Svoboda, MD, Sunita Dwivedy Nasta, MD, David Porter, MD, Daniel J. Landsburg, MD, Stephen J. Schuster, MD, Bruce D. Cheson, MD, Andrew M. Evens, DO, MSc
Journal: Blood
Blood (2015) 126 (23): 719.
https://doi.org/10.1182/blood.V126.23.719.719
Published: 2015
Journal Articles

Utilization of Next Generation Sequencing Identifies Potentially Actionable Mutations with Prognostic Significance in Chronic Lymphocytic Leukemia

Jie Wang, MD, Jennifer J.D. Morrissette, PhD, E. Paul Wileyto, PhD, Stephen J. Schuster, MD, Alexandra Vandegrift, BA, Allison Rago, BSN, Colleen Dorsey, BSN, David Porter, MD, Daniel J. Landsburg, MD, Prioty Islam, MD, Sunita Dwivedy Nasta, MD, Jakub Svoboda, MD, Alison Loren, MD MS, Scott Weber, BS, Edward A. Stadtmauer, MD, Anthony Mato, MD
Journal: Blood
Blood (2015) 126 (23): 2929.
https://doi.org/10.1182/blood.V126.23.2929.2929
Published: 2015